LPTX

LPTX Profile

  • Sector: Health Technology
  • Industry: Biotechnology
  • Employees: 26


Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Services We Offer

Need a custom stock scraper? Want to do some machine learning? We are here to help! Reach out to us!

Machine Learning

Custom Scraper

Automation

Consulting